Enanta制药 ENTA 深 沪
已收盘 02-06 16:00:00 美东时间
13.51
+0.540
+4.16%
华盛通- 最 高13.62
- 今 开13.22
- 成交量 16.40万股
- 最 低 13.22
- 昨 收 12.97
- 总市值 3.92亿
- 52周最高 17.15
- 市盈率 静 --
- 换手率 0.57%
- 52周最低 4.09
- 委 比 71.80%
- 总股本 2901.85万
- 历史最高 127.77
- 量 比 0.92
- 振 幅 3.08%
- 历史最低 4.09
- 每 手 1
- 风险率 3.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Enanta Pharmaceuticals Inc. Announces Date for Upcoming Annual Meeting of Stockholders
Enanta Pharmaceuticals Inc. Announces Date for Upcoming Annual Meeting of Stockholders Enanta Pharmaceuticals Inc. has announced that its 2026 Annual Meeting of Stockholders will be held virtually on March 11, 2026. During the meeting, shareholders will vote on the election of two Class I directors
01-27 05:06
美股大行评级 | 瑞穗上调英伟达、谷歌、美光科技、SanDisk多家科技股目标价；中金首予诺和诺德"跑赢大市"评级，目标价73.5美元
今日重点评级关注：Needham：维持Cartesian Therapeutics"买入"评级，目标价从40美元升至42美元；Piper Sandler：维持Acrivon Therapeutics"超配"评级，目标价从6美元升至8美元
01-12 14:09
Enanta Pharmaceuticals (ENTA) Receives a Buy from H.C. Wainwright
In a report released today, Brandon Folkes from H.C. Wainwright reiterated a Bu...
01-09 19:36
HC Wainwright & Co. Reiterates Buy on Enanta Pharma, Maintains $20 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates Enanta Pharma (NASDAQ:ENTA) with a Buy and maintains $20 price target.
01-09 19:32
Enanta Pharmaceuticals Reports Progress in Drug Development
Enanta Pharmaceuticals ( ($ENTA) ) has released its Q4 earnings. Here is a brea...
2025-11-18 12:02
Enanta Pharma Q4 EPS $(0.87) Beats $(1.03) Estimate, Sales $15.125M Miss $15.956M Estimate
Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(0.87) per share which beat the analyst consensus estimate of $(1.03) by 15.29 percent. This is a 36.03 percent increase over losses of $(1.36) per share from the
2025-11-18 05:02
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
2025-11-17 10:49
Enanta rises as J.P. Morgan starts at Overweight on RSV therapy
Shares of Enanta Pharmaceuticals traded higher on Friday after two straight sessions of losses as J.P. Morgan launched its coverage with an Overweight recommendation, citing the potential of zelicapav...
2025-11-15 00:54
JP Morgan Initiates Coverage On Enanta Pharma with Overweight Rating, Announces Price Target of $17
JP Morgan analyst Anupam Rama initiates coverage on Enanta Pharma (NASDAQ:ENTA) with a Overweight rating and announces Price Target of $17.
2025-11-14 20:28
Enanta Pharmaceuticals to Showcase RSV Drug Data at IDWeek 2025, Highlighting Two Oral Once-Daily Treatments
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that data for
2025-10-07 19:14
